Skip to main content
. Author manuscript; available in PMC: 2022 Feb 15.
Published in final edited form as: Clin Cancer Res. 2021 Mar 22;27(16):4478–4485. doi: 10.1158/1078-0432.CCR-20-4557

Table 3:

Efficacy Results by ICR in DESTINY-Breast01 (1,5)

Efficacy Parameter DESTINY-Breast01 HER2-positive Breast Cancer 5.4mg/kg (N = 184)
Confirmed Objective Response Rate (95% CI) 60.3% (52.9, 67.4)
Complete Response 4.3%
Partial Response 56%
Duration of Response* Median, months (95% CI)** 14.8 (13.8, 16.9)

ORR 95% CI calculated using Clopper-Pearson method

*

DOR is based on median duration of follow-up of 11.1 months.

**

Median DOR based on Kaplan-Meier estimate; 95% CI calculated using Brookmeyer-Crowley method